The Independent Standard for Pharmaceutical Reimbursement Risk
A Committee-Based Rating System Calibrated to Historical HTA Outcomes Across US, EU4, UK and Japan.
What MARA Rating Provides
MARA Rating is an independent, standardized assessment of pharmaceutical market access risk.
Regulatory approval does not guarantee reimbursement.
HTA agencies and payers act as a second gate.
MARA synthesizes evidence across 10 payer-relevant domains — including comparative effectiveness, safety, cost-effectiveness, budget impact, and evidence strength — into a single, comparable rating band (A++ to C).
The objective is not to replace judgment.
It is to reduce variance, surface hidden constraints, and provide a defensible benchmark before capital is committed.
How the MARA Rating Is Determined
Structured evaluation across 10 calibrated domains
Public, verifiable evidence sources only
Committee-based judgment; no single analyst determines outcome
Minutes recorded and conflict-of-interest controls enforced
Calibrated against historical HTA outcomes
Subject to defined surveillance and rating actions
Used in High-Stakes Decision Contexts
MARA Ratings are designed to support:
Pre-deal due diligence and valuation stress-testing
Phase 2 → Phase 3 investment decisions
Pre-launch pricing and reimbursement governance
Portfolio reprioritization
Investor memoranda and capital allocation discussions
Core principle:
If this decision is challenged later, what independent reimbursement benchmark was relied upon?
Rating Products
Single-Asset MARA Rating (Internal Use License)
Full committee-based rating with drivers, rationale, benchmarking, and surveillance status.
Therapeutic Area Benchmark Pack
Side-by-side rating comparison across assets within a defined therapeutic area.
Portfolio Access (Institutional License)
Structured access to multiple ratings and rating updates across defined asset groups.
Note: Public display of a MARA Rating requires a valid Display License.
Governance & Calibration
Published methodology framework
Defined rating action categories
Committee charter and conflict-of-interest controls
Calibration against retrospective HTA outcomes
Ongoing surveillance and periodic review
Rating Committee Charter
Annual Calibration Process
Obtain an independent reimbursement risk benchmark.
Methodology Overview (2 Minutes)
This short overview explains the structured evaluation process, committee governance, and calibration principles underlying the MARA Rating.
Check out our Youtube channel here.
Contact a MARA Analyst
Have a molecule in mind—or just a market access pharma question? Send us a note to sales@mararating.com and one of our analysts will reply within one business day. All inquiries are confidential.
"*" indicates required fields
Market Access & Capital Risk Insights
Contingent Value Rights in Pharma M&A: What Does It Mean for Market Access?
Summary Contingent value rights (CVRs) — conditional payments tied to regulatory approval, reimbursement milestones, or sales thresholds — have become
Bristol Myers Squibb and Hengrui Pharma’s $15.2 Billion Alliance: What Does It Mean for Market Access?
Bristol Myers Squibb and Hengrui Pharma announced a wide-ranging strategic agreement on May 12, 2026, covering 13 drug programs across
Lilly, Gilead Lead Pharma’s 2026 M&A Wave: What Does It Mean for Market Access?
Summary Eli Lilly and Gilead Sciences have each completed multiple acquisitions since the start of 2026, making this one of
UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases: what does it mean for Market Access?
Summary UCB, a Belgian pharmaceutical company, has announced a $2.2 billion deal to acquire Candid Therapeutics, a startup focused on
Chiesi to buy KalVista in $1.9B deal for rare disease drug: what does it mean for Market Access?
Chiesi Acquires KalVista: A Major Move in the Rare Disease Market Summary Chiesi Group, a family-owned Italian drugmaker, has announced
Teva nabs experimental Tourette drug in $700M Emalex buyout: what does it mean for Market Access?
Teva’s Strategic Move: Acquiring Emalex for Potential Tourette Syndrome Treatment Access impact Teva Pharmaceutical, known for its generic drugs, is